Literature DB >> 8081717

Does neurosteroid modulatory efficacy depend on GABAA receptor subunit composition?

G Puia1, I Ducić, S Vicini, E Costa.   

Abstract

The modulation of GABA activity by 3 alpha-OH-DHP (allopregnanolone, 3 alpha-hydroxy-5 alpha-pregnan-20-one) and PS (pregnenolone sulfate) has been studied in native GABAA receptors of rat cortical neurons in primary cultures and in structurally different recombinant GABAA receptors of rat cortical neurons in primary cultures and in structurally different recombinant GABAA receptors expressed in the 293 human embryonic kidney cell line (HEK 293). In cortical neurons 3 alpha-OH-DHP positively modulates GABA elicited Cl- currents while PS at 10 microM negatively modulates (50% decrease) this GABA response, but at 10 nM PS positively modulates the GABA current (40% increase). Both neurosteroids are equally active on various types of recombinant GABAA receptors, except for alpha 6 beta 1 gamma 2 receptors which are less sensitive to the positive allosteric modulation by 3 alpha-OH-DHP. In contrast the presence of the gamma 1 subunit doubles the efficacy of 3 alpha-OH-DHP. The negative modulation of PS is similar in recombinant GABAA receptors including various molecular forms of alpha or gamma units. A direct activation of Cl- current by 3 alpha-OH-DHP was observed in native and recombinant receptors but its efficacy on the various molecular forms of GABAA receptor tested was always smaller than that of identical concentrations (10 microM) of GABA.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8081717

Source DB:  PubMed          Journal:  Receptors Channels        ISSN: 1060-6823


  32 in total

1.  Neurosteroid modulation of GABA IPSCs is phosphorylation dependent.

Authors:  A Fáncsik; D M Linn; J G Tasker
Journal:  J Neurosci       Date:  2000-05-01       Impact factor: 6.167

Review 2.  Fluoxetine and norfluoxetine stereospecifically and selectively increase brain neurosteroid content at doses that are inactive on 5-HT reuptake.

Authors:  Graziano Pinna; Erminio Costa; Alessandro Guidotti
Journal:  Psychopharmacology (Berl)       Date:  2006-01-24       Impact factor: 4.530

3.  Markers in the 5'-region of GABRG1 associate to alcohol dependence and are in linkage disequilibrium with markers in the adjacent GABRA2 gene.

Authors:  Jonathan Covault; Joel Gelernter; Kevin Jensen; Raymond Anton; Henry R Kranzler
Journal:  Neuropsychopharmacology       Date:  2007-05-16       Impact factor: 7.853

Review 4.  Up-regulation of neurosteroid biosynthesis as a pharmacological strategy to improve behavioural deficits in a putative mouse model of post-traumatic stress disorder.

Authors:  Graziano Pinna; Ann M Rasmusson
Journal:  J Neuroendocrinol       Date:  2012-01       Impact factor: 3.627

5.  Enhanced neurosteroid potentiation of ternary GABA(A) receptors containing the delta subunit.

Authors:  Kai M Wohlfarth; Matt T Bianchi; Robert L Macdonald
Journal:  J Neurosci       Date:  2002-03-01       Impact factor: 6.167

Review 6.  The diversity of GABAA receptors. Pharmacological and electrophysiological properties of GABAA channel subtypes.

Authors:  W Hevers; H Lüddens
Journal:  Mol Neurobiol       Date:  1998-08       Impact factor: 5.590

7.  In socially isolated mice, the reversal of brain allopregnanolone down-regulation mediates the anti-aggressive action of fluoxetine.

Authors:  Graziano Pinna; Erbo Dong; Kinzo Matsumoto; Erminio Costa; Alessandro Guidotti
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-05       Impact factor: 11.205

8.  Delta subunit inhibits neurosteroid modulation of GABAA receptors.

Authors:  W J Zhu; J F Wang; K E Krueger; S Vicini
Journal:  J Neurosci       Date:  1996-11-01       Impact factor: 6.167

Review 9.  Neurosteroids and their role in sex-specific epilepsies.

Authors:  Doodipala Samba Reddy
Journal:  Neurobiol Dis       Date:  2014-06-21       Impact factor: 5.996

Review 10.  Molecular mechanisms of antiseizure drug activity at GABAA receptors.

Authors:  L John Greenfield
Journal:  Seizure       Date:  2013-05-14       Impact factor: 3.184

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.